Wading deeper into target discovery and validation, Immunai bags $60M to beef up both AI algorithms and lab benches
Noam Solomon and Luis Voloch set out, when they launched Immunai in 2018, to map out the immune system cell by cell.
The two engineers — who had met at MIT and like to illustrate their company’s stature by pointing out the number of employees who had been trained at Palantir, Google or Facebook — saw the potential in collating all the information churned out by a single cell-sequencing multi-omics platform. You can tell drugmakers what exactly is in their cell therapy products, profile for academics the immune response to their experimental treatments, or even suggest new biomarkers that seem to be relevant in a disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.